Tag - KZIA

Markets

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

October 14, 2021

Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021

Developments

Kazia presents positive interim data from Phase 2 glioblastoma trial

At the Society for Neuro-Oncology annual meeting, Kazia Therapeutics (NASDAQ:KZIA) presented positive interim data from its Phase 2 trial evaluating paxalisib for the treatment of diffuse intrinsic pontine glioma...

November 18, 2020

Developments

Kazia gets FDA fast track designation for glioblastoma

Kazia Therapeutics’ (NASDAQ:KZIA) paxalisib received FDA fast track designation for the treatment of glioblastoma. Interim data from the company’s Phase 2 trial demonstrated overall survival of 17.7 months for patients...

August 20, 2020

Developments

Kazia gets FDA rare pediatric disease designation for paxalisib

Kazia Therapeutics (NASDAQ:KZIA) received FDA rare pediatric disease designation for paxalisib for the treatment of diffuse intrinsic pontine glioma (DIPG). Paxalisib is currently in a Phase 1 trial for DIPG. Positive...

August 7, 2020

Tag - KZIA

Maxim starts Kazia Therapeutics at buy; PT $18

HCW starts Kazia Therapeutics at buy; PT $17

Kazia presents positive interim data from Phase 2 glioblastoma trial

Kazia gets FDA fast track designation for glioblastoma

Kazia gets FDA rare pediatric disease designation for paxalisib

General

More